ID   Ishikawa-RP
AC   CVCL_IJ14
SY   Ishikawa-Resistant to Progestin
DR   cancercelllines; CVCL_IJ14
DR   Wikidata; Q54898304
RX   PubMed=23255909;
CC   Population: Japanese.
CC   Doubling time: 34.18 +- 3.15 hours (PubMed=23255909).
CC   Selected for resistance to: ChEBI; CHEBI_6716; Medroxyprogesterone acetate (MPA).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C40145; Type I endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2529 ! Ishikawa
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 11
//
RX   PubMed=23255909; DOI=10.3892/ol.2012.975; PMCID=PMC3525505;
RA   Zhao S.-J., Li G.-X., Yang L., Li L., Li H.-Y.;
RT   "Response-specific progestin resistance in a newly characterized
RT   Ishikawa human endometrial cancer subcell line resulting from
RT   long-term exposure to medroxyprogesterone acetate.";
RL   Oncol. Lett. 5:139-144(2013).
//